References:†:Medical Insight, Inc 2016. Global Facial Injectables Market Study. November 2016. Based on worldwide neurotoxins market 2015 (in sales value).
*: Allergan reaches historic BOTOX^® milestone with 100 million vials, Aesthetic Medicine, 16 April 2019.https://aestheticmed.co.uk/site/industrynewsdetails/allergan-reaches-historic-botox-milestone-with-100-million-vials.
1. Allergan. Medical Aesthetic Day. September 2018. Therapeutic and aesthetic use. 2. Allergan. Data on file. INT/0721/2017. September 2017. 3. DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Decker, Inc; 1994: 15-39. 4. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:3-13. 5. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:41-49. 6. Simpson LL. The actions of clostridial toxins on storage and release of neurotransmitters. In: Harvey AL, ed. Natural and Synthetic Neurotoxins (Neuroscience Perspectives). San Diego, CA: Academic Press; 1993:278-317. 7. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103(2):535-544. 8. Lebeda FJ, Hack DC, Bentry MK. Theoretical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallet M, ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:51-61. 9. Harvey AL. Presynaptic toxins. In: Smythies JR, Bradley RJ, ed. International Review of. 10. Neurobiology. San Diego, CA: Academic Press; 1990:201-239. 11. Stotland MA et al. Plast Reconstr Surg 2007; 120(5):1386-9. 12. Trindade de Almeida A et al. Dermatol Surg 2015; 41: S19-S28. 13. Beer KR et al. J Drugs Dermatol 2011;10:39-41. 14. Hyperhidrosis- Causes and Treatment of Enhanced Sweating. Dtsch Arztebl Int. 2009 Jan; 106(3):32-37. 15. Aesthetic Surg J. 2012 Feb;32(2):238-244; 16. J Am Acad Dermatol. 2007 Apr; 56(4):604-11. 17. He J, Wang T and Dong J. Journal of Dermatological Treatment. 2012; 23: 461–464. 18. Naumann M and Lowe NJ. BMJ 2001;323:1–4. 19. Lowe NJ et al. J Am Acad Dermatol. 2007;56(4):604-611. 20. Glogau R et al. Dermatol Surg. 2012;38:1794-1803. Average dosing: 20U for gabellar lines. 21. Baumann L et al. Dermatol Surg. 2016;42:598–607. Average dosing: 24U for crow feet lines. 22. BOTOX^® Prescribing Information. HK-41906. May 2013. 23. Inoue K et al. Infect Immun 1996;65:1589-94.

BOTOX^®保妥適^®為醫生處方藥物，請向醫生或醫療美容診所諮詢切合您獨特需要的專屬療程方案。
療程效果因人而異。療程後如有任何不良反應，請即向醫生查詢。
BOTOX^®和保妥適^®是愛力根藥廠已註冊的商業名稱。^®及^TM為愛力根藥廠的註冊商標。HK-BCT-1950039.